# Federal Policy Advocacy Strategy

**Document Version**: 1.0
**Last Updated**: November 7, 2025
**Owner**: Director of Advocacy & Policy
**Purpose**: Strategy for federal-level advocacy to improve AATD diagnosis, treatment, and research

---

## üìã Table of Contents

1. [Federal Policy Landscape](#federal-policy-landscape)
2. [Legislative Priorities](#legislative-priorities)
3. [Regulatory Priorities](#regulatory-priorities)
4. [Federal Agency Engagement](#federal-agency-engagement)
5. [Congressional Advocacy](#congressional-advocacy)
6. [Coalition Strategy](#coalition-strategy)
7. [Success Metrics](#success-metrics)

---

## Federal Policy Landscape

### Current Federal Context for AATD

**Strengths**:

- ‚úÖ NIH funds some AATD research (limited, competitive)
- ‚úÖ FDA regulates augmentation therapy (4 approved products)
- ‚úÖ Medicare/Medicaid covers AATD testing and treatment (with limitations)
- ‚úÖ Rare disease designation (AATD is recognized as rare disease)

**Gaps & Challenges**:

- ‚ùå **No federal AATD screening mandate** (unlike newborn screening for other genetic conditions)
- ‚ùå **Low research funding** (AATD is "rare" but not rare enough for Orphan Drug Act incentives in practice)
- ‚ùå **Insurance barriers** (prior authorization, step therapy, high copays for augmentation therapy)
- ‚ùå **Diagnostic delays not prioritized** (no federal initiative to reduce diagnostic delays)
- ‚ùå **Limited awareness among policymakers** (most don't know what AATD is)

---

### Federal Agencies Relevant to AATD

**1. National Institutes of Health (NIH)**:

- **Role**: Fund AATD research (basic, translational, clinical)
- **Key Institutes**: NHLBI (lung), NIDDK (liver), NICHD (pediatric), NIGMS (genetics)
- **Opportunity**: Increase AATD research funding

**2. Centers for Disease Control and Prevention (CDC)**:

- **Role**: Public health surveillance, disease prevention
- **Opportunity**: Add AATD to CDC rare disease tracking, promote screening

**3. Food and Drug Administration (FDA)**:

- **Role**: Approve diagnostics, therapeutics, devices
- **Opportunity**: Expedited review for AATD diagnostics (AAT glucometer), new treatments

**4. Centers for Medicare & Medicaid Services (CMS)**:

- **Role**: Reimbursement policies for testing, treatment
- **Opportunity**: Expand coverage, reduce prior authorization barriers

**5. Health Resources and Services Administration (HRSA)**:

- **Role**: Healthcare workforce, underserved populations
- **Opportunity**: AATD patient navigation programs, community health center grants

**6. Agency for Healthcare Research and Quality (AHRQ)**:

- **Role**: Healthcare quality, patient safety, evidence-based practices
- **Opportunity**: AATD diagnostic delay research, quality improvement initiatives

---

## Legislative Priorities

### Priority 1: AATD Early Detection Act üî• (HIGH PRIORITY)

**Goal**: Federal legislation to improve early detection of AATD

**Key Provisions**:

1. **Targeted Screening Mandate**:
   - Require AATD testing for all individuals diagnosed with COPD (unless previously tested)
   - Rationale: 50%+ of AATD patients misdiagnosed with COPD; testing this population captures many undiagnosed

2. **Cascade Screening**:
   - Once one family member diagnosed, require insurance to cover genetic testing for first-degree relatives (parents, siblings, children)
   - Rationale: AATD is genetic‚Äîtesting family members identifies more cases

3. **Provider Education Funding**:
   - $5M/year to CDC or HRSA for AATD provider education (CME, toolkits, awareness campaigns)
   - Rationale: Providers don't test because they don't think of AATD‚Äîeducation increases detection

4. **Data Collection**:
   - Require CDC to track AATD prevalence, diagnostic delays, health outcomes
   - Rationale: Can't improve what you don't measure

**Status**: Draft legislation being developed (Year 1-2)

**Strategy**:

- Champion identification (find bipartisan congressional champion‚Äîideally someone with personal AATD connection)
- Coalition building (partner with Alpha-1 Foundation, American Lung Association, rare disease coalitions)
- Patient stories (bring AATD patients to Capitol Hill to share diagnostic delay stories)

**Timeline**:

- **2026**: Draft bill, identify champion
- **2027**: Introduce bill in House and Senate
- **2028**: Committee hearings, advocacy push
- **2029**: Floor vote (if momentum)
- **2030**: Passage (aspirational)

---

### Priority 2: Rare Disease Research Funding Increase

**Goal**: Increase NIH funding for rare disease research (including AATD)

**Mechanism**: Congressional appropriations (annual budget process)

**Ask**:

- **NIH Rare Disease Research**: Increase by $100M/year
- **NHLBI AATD Program**: Dedicated $10M/year for AATD research (within NIH budget)

**Strategy**:

- Join rare disease coalitions (NORD, EveryLife Foundation, Genetic Alliance)
- Annual "Rare Disease Week" advocacy (February‚ÄîRare Disease Day)
- Congressional letters (ask Members of Congress to sign letter to Appropriations Committee)
- Senate/House Appropriations Committee testimony (submit written testimony, request speaking slot)

**Timeline**: Annual (every budget cycle)

---

### Priority 3: Medicare/Medicaid Coverage Expansion

**Goal**: Expand Medicare/Medicaid coverage for AATD services

**Specific Asks**:

1. **Eliminate Prior Authorization for Augmentation Therapy**:
   - Current: Many states require prior auth (delays treatment 30-90 days)
   - Proposed: Automatic approval if AAT level <11 ¬µM (57 mg/dL) + ZZ or SZ genotype
   - Rationale: Delays harm patients (lung function declines)

2. **Cover Genetic Testing**:
   - Current: Some states don't cover genetic testing (only AAT level)
   - Proposed: Require coverage of genotyping (Pi*Z, Pi*S allele testing)
   - Rationale: Genotype determines eligibility for augmentation therapy

3. **Cover Patient Navigation**:
   - Proposed: Medicare/Medicaid reimbursement for AATD patient navigators
   - Rationale: Navigation reduces diagnostic delays, improves treatment adherence

**Mechanism**:

- CMS rulemaking (comment on proposed rules)
- Congressional oversight (ask Health Subcommittee to hold hearing on AATD coverage barriers)

**Timeline**:

- **2026**: Submit comment letters to CMS
- **2027**: Congressional hearing (if opportunity arises)
- **2028-2030**: Policy changes (if advocacy successful)

---

### Priority 4: Newborn Screening for AATD

**Goal**: Add AATD to federal Recommended Uniform Screening Panel (RUSP)

**Background**:

- **RUSP**: Federal advisory committee recommends which conditions should be included in state newborn screening programs
- **Current status**: AATD is NOT on RUSP (some states screen voluntarily, most don't)

**Rationale**:

- ‚úÖ AATD is genetic (present at birth)
- ‚úÖ Simple blood test (AAT level + genotype)
- ‚úÖ Early detection enables:
  - Avoid smoking (prevent lung disease)
  - Avoid harmful occupations (dust, fumes)
  - Early treatment (if liver disease)
  - Family screening (cascade testing)

**Challenge**:

- ‚ùå No immediate treatment for most babies with AATD (unlike PKU, hypothyroidism)
- ‚ùå Ethical concerns (genetic information, insurance discrimination)
- ‚ùå High bar for RUSP inclusion (must meet evidence criteria)

**Strategy**:

- Long-term goal (5-10 years)
- Build evidence base (research studies showing benefit of early detection)
- Pilot programs (partner with 2-3 states to pilot newborn screening)
- Coalition building (pediatricians, genetic counselors, patient groups)

**Timeline**:

- **2026-2028**: Research + pilot programs
- **2029-2030**: RUSP application submitted
- **2031-2035**: RUSP review + decision (aspirational)

---

### Priority 5: Insurance Non-Discrimination Protections

**Goal**: Strengthen protections against genetic discrimination

**Background**:

- **GINA (Genetic Information Nondiscrimination Act, 2008)**: Prohibits health insurance + employment discrimination based on genetic information
- **Gap**: GINA does NOT cover life insurance, disability insurance, long-term care insurance

**Problem for AATD Patients**:

- Many patients denied life insurance or charged higher premiums after AATD diagnosis
- Discourages people from getting tested (fear of discrimination)

**Proposed Solution**:

- Expand GINA to cover life insurance, disability insurance, long-term care insurance
- Or: Pass separate "Genetic Privacy Act"

**Strategy**:

- Join existing coalitions (many rare disease groups face this issue)
- Patient stories (AATD patients denied life insurance)
- Bipartisan support (privacy is bipartisan issue)

**Timeline**:

- **2027-2030**: Advocacy campaign
- **2030+**: Legislation introduced (long-term goal)

---

## Regulatory Priorities

### Priority 1: FDA Fast Track for AATD Diagnostics

**Goal**: Expedited FDA review for novel AATD diagnostics

**Target**: AAT glucometer (Mark Egly's patent, US20220160847)

**Mechanism**:

- **FDA Fast Track Designation**: Expedites development and review of drugs/devices for serious conditions
- **FDA Breakthrough Device Designation**: Expedites devices that provide more effective treatment/diagnosis

**Strategy**:

- Meet with FDA (pre-submission meeting)
- Demonstrate: AATD is serious condition, diagnostic delay is significant problem, glucometer would improve early detection
- Submit Fast Track or Breakthrough Device application

**Timeline**:

- **2027**: FDA pre-submission meeting
- **2028**: Fast Track/Breakthrough Device designation (if glucometer development progresses)
- **2029-2030**: FDA approval (if device successful)

---

### Priority 2: CMS Coverage for Home Testing

**Goal**: Medicare/Medicaid coverage for home-based AATD testing

**Background**:

- Currently: AATD testing requires doctor's order + lab visit
- Proposed: Home-based testing (finger prick, mail to lab OR home glucometer)
- Benefit: Increases access (especially rural, underserved populations)

**Mechanism**:

- CMS National Coverage Determination (NCD) or Local Coverage Determination (LCD)

**Strategy**:

- Submit coverage application to CMS
- Provide evidence: Home testing is accurate, increases detection rates, cost-effective
- Coalition support: Patient groups, medical societies

**Timeline**:

- **2028**: Submit coverage application (once home testing validated)
- **2029**: CMS review
- **2030**: Coverage decision (aspirational)

---

### Priority 3: FDA Guidance on AATD Clinical Trials

**Goal**: FDA guidance document for AATD clinical trial design

**Need**:

- AATD is rare‚Äîsmall patient populations make traditional RCTs difficult
- Need FDA guidance on acceptable trial designs (adaptive trials, real-world evidence)

**Strategy**:

- Convene stakeholders (FDA, NIH, industry, patient groups)
- Develop consensus recommendations
- Submit to FDA (request guidance document)

**Timeline**:

- **2027-2028**: Stakeholder meetings
- **2029**: Submit recommendations to FDA
- **2030**: FDA publishes guidance (if successful)

---

## Federal Agency Engagement

### NIH Engagement Strategy

**Goal**: Increase NIH funding for AATD research

**Tactics**:

1. **Scientific Workshops**:
   - Co-sponsor NIH workshop on "AATD Diagnostic Delays: Research Priorities"
   - Bring together researchers, clinicians, patients to identify research gaps
   - Publish proceedings (raise profile)

2. **Funding Opportunity Announcements (FOAs)**:
   - Encourage NIH to issue AATD-specific FOAs (targeted funding opportunities)
   - Work with NHLBI, NIDDK program officers

3. **National Advisory Council**:
   - Patient representative on NHLBI Advisory Council (advocate for AATD research funding)

4. **Data Sharing**:
   - Offer Foundation's AATD Research Database to NIH-funded researchers (accelerate research)

---

### CDC Engagement Strategy

**Goal**: Add AATD to CDC rare disease surveillance

**Tactics**:

1. **Rare Disease Registry**:
   - Advocate for AATD inclusion in CDC's National Rare Disease Registry (if/when established)

2. **Public Health Campaign**:
   - Partner with CDC on AATD awareness campaign (similar to CDC's COPD campaigns)

3. **State Health Departments**:
   - Provide AATD toolkits to state health departments (via CDC channels)

---

### HRSA Engagement Strategy

**Goal**: Fund AATD patient navigation through HRSA programs

**Tactics**:

1. **Patient Navigator Programs**:
   - Encourage HRSA to prioritize AATD in Patient Navigator grant programs

2. **Community Health Centers**:
   - Partner with HRSA-funded community health centers (offer AATD screening, education)

3. **Rural Health**:
   - AATD screening in rural areas (via HRSA's Office of Rural Health Policy)

---

## Congressional Advocacy

### Building Congressional Champions

**Goal**: Identify and cultivate congressional champions for AATD

**Target**:

- Members of Congress with personal AATD connection (patient, family member, constituent)
- Members on key committees:
  - House Energy & Commerce (health jurisdiction)
  - Senate HELP (Health, Education, Labor, Pensions)
  - House/Senate Appropriations (funding)
- Bipartisan (AATD is not political‚Äîaffects Republicans, Democrats, Independents equally)

**Strategy**:

1. **Identify Targets**:
   - Research: Which Members have AATD constituents? (Alpha-1 Foundation member data, support groups)
   - Outreach: Contact Members' health staff

2. **Educate**:
   - One-pagers: "AATD 101 for Congressional Staff"
   - Capitol Hill briefings: Lunch-and-learn sessions (food + education)
   - Patient visits: AATD patients meet with Members in DC or district

3. **Engage**:
   - Invite Members to AATD events (awareness walks, support group meetings)
   - Recognize champions: Awards, public thank-yous

4. **Ask**:
   - Co-sponsor legislation (AATD Early Detection Act)
   - Sign letters (appropriations letters, agency letters)
   - Congressional hearings (request hearings on AATD)

---

### Congressional Hearing Strategy

**Goal**: Congressional hearing on AATD diagnostic delays

**Target Committee**: House Energy & Commerce Health Subcommittee (or Senate HELP)

**Hearing Title**: _"Diagnostic Delays in Rare Diseases: The Case of Alpha-1 Antitrypsin Deficiency"_

**Witnesses** (proposed):

- **AATD patient** (tell story of 7-8 year diagnostic delay‚ÄîMark Egly?)
- **AATD expert physician** (pulmonologist or hepatologist)
- **NIH representative** (discuss research needs)
- **Patient advocate** (Mark Egly Foundation or Alpha-1 Foundation)

**Outcomes**:

- Raise profile of AATD
- Media coverage (C-SPAN, health press)
- Congressional record (creates permanent record)
- Momentum for legislation

**Timeline**:

- **2027**: Request hearing (via Congressional champion)
- **2028**: Hearing held (if successful)

---

### Annual Advocacy Day

**Event**: "AATD Advocacy Day on Capitol Hill"

**When**: February (Rare Disease Month)

**Participants**: 50-100 AATD patients, caregivers, advocates

**Schedule**:

- **Day 1 (evening)**: Advocacy training (how to tell your story, how to meet with Members)
- **Day 2 (full day)**: Capitol Hill visits (meetings with Members of Congress and staff)
- **Day 3 (morning)**: Capitol Hill briefing (public event, panel discussion on AATD)

**Outcomes**:

- 100-200 congressional meetings/year
- Media coverage (local + national)
- Build relationships (ongoing engagement with Congress)

**Budget**: $50K/year (Year 3+)

---

## Coalition Strategy

### National Coalitions (Join/Lead)

**1. National Organization for Rare Disorders (NORD)**:

- **Role**: Lead coalition for rare disease policy advocacy
- **Benefits**: Access to 300+ rare disease groups, shared policy priorities, collective advocacy
- **MEF Role**: Active member, contribute to rare disease legislative priorities

**2. EveryLife Foundation for Rare Diseases**:

- **Role**: Rare disease research funding advocacy
- **Benefits**: NIH budget advocacy, research policy expertise
- **MEF Role**: Member, participate in Rare Disease Week advocacy

**3. Genetic Alliance**:

- **Role**: Genetic disease advocacy, genetic privacy
- **Benefits**: GINA expansion advocacy, newborn screening expertise
- **MEF Role**: Member, collaborate on genetic privacy campaigns

**4. National Health Council**:

- **Role**: Coalition of 160+ health organizations
- **Benefits**: Broad health policy advocacy (Medicare, Medicaid, FDA, etc.)
- **MEF Role**: Member (if eligible‚Äîrequires certain organizational criteria)

---

### Disease-Specific Coalitions (Build)

**Lung Disease Coalition**:

- **Partners**: American Lung Association, COPD Foundation, Pulmonary Fibrosis Foundation, Asthma and Allergy Foundation
- **Shared Priority**: Lung health funding, clean air policies, tobacco control
- **MEF Role**: Co-lead on AATD-specific issues, contribute to broader lung health advocacy

**Liver Disease Coalition**:

- **Partners**: American Liver Foundation, Hepatitis B Foundation, Fatty Liver Foundation
- **Shared Priority**: Liver disease research, screening, treatment access
- **MEF Role**: Contribute expertise on genetic liver disease (AATD)

---

### State-Level Coalitions

**State Rare Disease Advisory Councils**:

- Many states have rare disease councils (advocate for state-level rare disease policies)
- **MEF Strategy**: Join state councils in key states (Florida, California, New York, Texas)

---

## Success Metrics

### Short-Term (1-2 years)

**Awareness**:

- # Congressional offices educated about AATD (target: 50 offices by Year 2)
- # Congressional champions identified (target: 5 bipartisan champions by Year 2)

**Engagement**:

- # Advocacy Day participants (target: 50 by Year 2)
- # Congressional meetings (target: 100 meetings/year by Year 2)

**Policy Development**:

- AATD Early Detection Act drafted (Year 1-2)
- Congressional champion identified (Year 2)

---

### Medium-Term (3-5 years)

**Legislative Progress**:

- AATD Early Detection Act introduced in House and Senate (Year 3)
- Congressional hearing on AATD held (Year 3-4)
- Bill passed out of committee (Year 4-5, aspirational)

**Funding Increases**:

- NIH AATD research funding increased 20% (Year 3-5)
- HRSA patient navigation grant secured ($500K, Year 4)

**Regulatory Wins**:

- FDA Fast Track designation for AAT glucometer (Year 4, if device progresses)

---

### Long-Term (5-10 years)

**Legislative Wins**:

- AATD Early Detection Act passed into law (Year 5-7, aspirational)
- Rare disease research funding increased significantly ($100M+)

**Policy Changes**:

- CMS eliminates prior authorization for augmentation therapy (Year 7-10)
- AATD added to RUSP (newborn screening) (Year 10+, long-term goal)

**System Change**:

- Diagnostic delay reduced from 7-8 years to 3-4 years (2030 goal)
- 50% of undiagnosed AATD patients identified (vs. 10% today)

---

## Summary

**Mark Egly Foundation Federal Policy Advocacy Strategy**:

- ‚úÖ **Legislative Focus**: AATD Early Detection Act (screening mandate, provider education, data collection)
- ‚úÖ **Regulatory Focus**: FDA Fast Track for diagnostics, CMS coverage expansion
- ‚úÖ **Agency Engagement**: NIH (research $), CDC (surveillance), HRSA (patient navigation)
- ‚úÖ **Congressional Advocacy**: Champions, hearings, Advocacy Day
- ‚úÖ **Coalition Strategy**: NORD, EveryLife, Genetic Alliance, lung/liver coalitions

**Year 1 Priorities**:

- Draft AATD Early Detection Act
- Identify 2-3 Congressional champions
- Join NORD, EveryLife, Genetic Alliance
- Submit CMS comment letters (coverage issues)

**Year 5 Goals**:

- AATD Early Detection Act introduced (both chambers)
- Congressional hearing held
- NIH AATD funding increased 20%
- 5-10 bipartisan champions
- Annual Advocacy Day (50-100 participants)

**Policy change is slow, but essential for long-term impact.**

---

**Questions?**

**Mark Egly Foundation**
üìß Email: policy@markeglyfoundation.org
üåê Website: MarkEglyFoundation.org/Advocacy

---

**Approved by**: Board of Directors
**Effective Date**: January 1, 2026
**Review Date**: Annually
**Version**: 1.0

---

_"Policy is patients. Advocacy is action."_

**‚Äî Mark Egly Foundation**
